Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.AkaRx and MGI Pharma close development and license deal
In accordance with the terms of the transaction, MGI Pharma has made payments of $45 million, in the aggregate, to AkaRx and its shareholders to acquire certain license
In accordance with the terms of the transaction, MGI Pharma has made payments of $45 million, in the aggregate, to AkaRx and its shareholders to acquire certain license
The diagnostic tests rely on circulating tumor cells in patients’ blood. Innogenetics entered into the agreement following the successful conclusion of a feasibility study to convert the current
The marketing authorization application seeks approval for oral alitretinoin for the treatment of severe refractory chronic hand eczema (CHE) and is based on a clinical program comprising almost
Through the collaboration, Campbell University’s experts in pharmaceutical product development will initiate a program to develop a novel formulation for ear infections in children. Jarrett Disbrow, president and
Based on these results, Curagen is discontinuing the development of velafermin, and will continue to focus its resources on belinostat, a Phase II histone deacetylase inhibitor for the
The Phase II study is designed to treat patients with stable coronary artery disease (CAD) undergoing percutaneous coronary intervention (PCI). The company has also announced top-line results from
Viread has already been approved in the US and EU for the treatment of HIV as part of combination antiretroviral therapy. The submissions contain data from two Phase
Results from this international, multi-center, randomized, double-blind, placebo-controlled study have demonstrated that Lamictal XR reduced partial seizures by 46% over the entire 19-week treatment period, compared to 24%
According to the company, this significant reduction was seen as early as week one. The common adverse drug reactions (greater than or equal to 5% of either desvenlafaxine
This indication is based on analyses of plasma HIV-1 RNA levels up through 24 weeks in two controlled studies of Isentress (raltegravir). These studies were conducted in clinically